May 11, 2026 – Cardinal Health, one of the US’s largest manufacturers of radiopharmaceuticals, announced that it is expanding its production of actinium-225, a radionuclide used for cancer treatment, at a facility in Indianapolis, Indiana.
The news comes on the heels of a recent announcement from Shine Technologies — one of Cardinal’s suppliers — that it is now exporting its own medical isotope, lutetium-177, from its production site in Wisconsin to China though Chinese radiopharmaceutical company C-Ray.
The US typically relies on overseas reactors for critical radiopharmaceuticals, something that the Trump administration has expressed a desire to change. In press releases for both announcements, Cardinal Health and Shine underscored the impact their latest advancements will have on the US radiopharmaceutical supply chain and increasing demand.